Prime Discoveries is a biotechnology company specializing in the development of rapid and novel diagnostic tests for COVID-19 and its variants, including Omicron. The company serves diagnostic laboratories that require scalable solutions to process high volumes of samples efficiently. Operating in the healthcare diagnostics market, Prime Discoveries leverages a state-of-the-art technology platform that integrates automation, machine learning, and computational biology to accelerate the discovery and deployment of reliable assays. The business model focuses on providing customizable diagnostic panels that can be tailored to fit the specific workflows of partner laboratories. Revenue is generated through the sale of these diagnostic tests, with pricing models that offer lower costs per sample based on volume. Prime Discoveries collaborates with academic institutions and utilizes ISO-certified contract manufacturing organizations (CMOs) in the U.S. to ensure a robust supply chain and quick turnaround times. The company’s offerings are designed for research use and are not intended for direct clinical diagnosis, treatment, or prevention of diseases.

Keywords: COVID-19 diagnostics, Omicron detection, high-throughput labs, automation, machine learning, computational biology, customizable assays, scalable solutions, biotechnology, healthcare diagnostics.